The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Treatment of cocaine cardiovascular toxicity: a systematic review
Abstract
INTRODUCTION: Cocaine abuse is a major worldwide health problem. Patients with acute cocaine toxicity presenting to the emergency department may require urgent treatment for tachycardia, dysrhythmia, hypertension, and coronary vasospasm, leading to pathological sequelae such as acute coronary syndrome, stroke, and death. OBJECTIVE: The objective of this study is to review the current evidence for pharmacological treatment of cardiovascular toxicity resulting from cocaine abuse. METHODS: MEDLINE, PsycINFO, Database of Abstracts of Reviews of Effects (DARE), OpenGrey, Google Scholar, and the Cochrane Library were searched from inception to November 2015. Articles on pharmacological treatment involving human subjects and cocaine were selected and reviewed. Evidence was graded using Oxford Centre for Evidence-Based Medicine guidelines. Treatment recommendations were compared to current American College of Cardiology/American Heart Association guidelines. Special attention was given to adverse drug events or treatment failure. The search resulted in 2376 articles with 120 eligible involving 2358 human subjects. Benzodiazepines and other GABA-active agents: There were five high-quality (CEBM Level I/II) studies, three retrospective (Level III), and 25 case series/reports (Level IV/V) supporting the use of benzodiazepines and other GABA-active agents in 234 subjects with eight treatment failures. Benzodiazepines may not always effectively mitigate tachycardia, hypertension, and vasospasm from cocaine toxicity. Calcium channel blockers: There were seven Level I/II, one Level III, and seven Level IV/V studies involving 107 subjects and one treatment failure. Calcium channel blockers may decrease hypertension and coronary vasospasm, but not necessarily tachycardia. Nitric oxide-mediated vasodilators: There were six Level I/II, one Level III, and 25 Level IV/V studies conducted in 246 subjects with 11 treatment failures and two adverse drug events. Nitroglycerin may lead to severe hypotension and reflex tachycardia. Alpha-adrenoceptor blocking drugs: There were two Level I studies and three case reports. Alpha-1 blockers may improve hypertension and vasospasm, but not tachycardia, although evidence is limited. Alpha-2-adrenoceptor agonists: There were two high-quality studies and one case report detailing the successful use of dexmedetomidine. Beta-blockers and β/α-blockers: There were nine Level I/II, seven Level III, and 34 Level IV/V studies of β-blockers, with 1744 subjects, seven adverse drug events, and three treatment failures. No adverse events were reported for use of combined β/α-blockers such as labetalol and carvedilol, which were effective in attenuating both hypertension and tachycardia. Antipsychotics: Seven Level I/II studies, three Level III studies, and seven Level IV/V case series and reports involving 168 subjects have been published. Antipsychotics may improve agitation and psychosis, but with inconsistent reduction in tachycardia and hypertension and risk of extrapyramidal adverse effects. Other agents: There was only one high level study of morphine, which reversed cocaine-induced coronary vasoconstriction but increased heart rate. Other agents reviewed included lidocaine, sodium bicarbonate, amiodarone, procainamide, propofol, intravenous lipid emulsion, propofol, and ketamine. CONCLUSIONS: High-quality evidence for pharmacological treatment of cocaine cardiovascular toxicity is limited but can guide acute management of associated tachycardia, dysrhythmia, hypertension, and coronary vasospasm. Future randomized prospective trials are needed to evaluate new agents and further define optimal treatment of cocaine-toxic patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The exact mechanism of action of modafinil is unclear, though in vitro studies have shown that it modulates multiple neurotransmitter systems, including dopamine, serotonin, and norepinephrine reuptake, as well as histamine and hypocretin signaling.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [130]
In the citing paper
“Modafinil also activates glutamatergic circuits while inhibiting GABA.130,131”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [130]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Self-citationAnderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 960
Cocaine-Induced Coronary-Artery Vasoconstriction
Lange, R. A., Cigarroa, R. G., Yancy, C. W., Willard, J. E., Popma, J. J., Sills, M. N., McBride, W., Kim, A. S., & Hillis, L. D. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912073212301 · Cited by 619
Self-citationMcCord, J., Jneid, H., Hollander, J. E., de Lemos, J. A., Cercek, B., Hsue, P., Gibler, W. B., Ohman, E. M., Drew, B., Philippides, G., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188950 · Cited by 429
Research works printed but not linked: 12
- Lombard J, 1988, West J Med, 148, 466
- Ní Chróinín D, 2012, Ir Med J, 105, 118
- Rollingher IM, 1986, CMAJ, 135, 45
- Coleman DL, 1982, West J Med, 136, 444
- Rummel TS., 1989, J Tenn Med Assoc, 82, 541
- Stenberg RG, 1989, Arch Pathol Lab Med, 113, 521
- Grewal RP, 1991, Acta Neurol (Napoli), 13, 279
- Martinez-Quintana E, 2013, Int J Endocrinol Metab, 11, 48
- Burton KR, 1989, J Clin Psychiatry, 50, 305
- Williams RG, 1996, Can J Cardiol, 12, 1295
- Cox RD, 2004, Vet Hum Toxicol, 46, 21
- Grigorov V, 2004, Cardiovasc J S Afr, 15, 139
Cited by
Panchal, A. R., Bartos, J. A., Cabañas, J. G., Donnino, M. W., Drennan, I. R., Hirsch, K. G., Kudenchuk, P. J., Kurz, M. C., Lavonas, E. J., Morley, P. T., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000916 · Cited by 2,105
Topjian, A. A., Raymond, T. T., Atkins, D., Chan, M., Duff, J. P., Joyner, B. L., Lasa, J. J., Lavonas, E. J., Levy, A., Mahgoub, M., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000901 · Cited by 1,258
European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances
Lott, C., Truhlář, A., Alfonzo, A., Barelli, A., González-Salvado, V., Hinkelbein, J., Nolan, J. P., Paal, P., Perkins, G. D., Thies, K.-C., et al. (2021) · Resuscitation · doi:10.1016/j.resuscitation.2021.02.011 · Cited by 789
Lavonas, E. J., Akpunonu, P. D., Arens, A. M., Babu, K. M., Cao, D., Hoffman, R. S., Hoyte, C. O., Mazer-Amirshahi, M. E., Stolbach, A., St-Onge, M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001161 · Cited by 189
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Metadata
- Authors
- Richards, J. R., Garber, D., Laurin, E. G., Albertson, T. E., Derlet, R. W., Amsterdam, E. A., Olson, K. R., Ramoska, E. A., & Lange, R. A.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, San Francisco (US)
- Drexel University (US)
- Texas Tech University Health Sciences Center (US)
- Corresponding author
- Richards, John R.
- ORCID
- Venue
- Clinical Toxicology
- Publisher
- Informa UK Limited
- Published
- 2016-02-26
- Volume
- 54
- Issue
- 5
- Pages
- 345-364
- ISSN
- 0009-9309 (ISSN-L)
- 1556-3650
- 1556-9519
- OpenAlex
- W2288746277
- Cited by
- 116
- References
- 151
- Citations by year
- 2026: 9 · 2025: 4 · 2024: 10 · 2023: 7 · 2022: 14 · 2021: 17 · 2020: 14 · 2019: 10 · 2018: 10 · 2017: 12 · 2016: 9
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- cocaine abuse, pharmacotherapy, benzodiazepines, calcium channel blockers, nitroglycerin, alpha-1 adrenergic blockers, dexmedetomidine, beta-blockers, tachycardia, hypertension, coronary vasospasm, acute coronary syndrome, stroke, treatment failure, adverse drug reactions, emergency department management, ACC/AHA guidelines
- MeSH terms
- Benzodiazepines, Calcium Channel Blockers, Cardiovascular System, Cocaine, Heart Rate, Humans, Hypertension, Nitric Oxide, Tachycardia, Vasodilator Agents, Randomized Controlled Trials as Topic, Evidence-Based Medicine, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of cocaine cardiovascular toxicity: a systematic review. https://app.cochat.ai/papers/10.3109/15563650.2016.1142090
- The paper
- Richards, J. R., Garber, D., Laurin, E. G., Albertson, T. E., Derlet, R. W., Amsterdam, E. A., Olson, K. R., Ramoska, E. A., & Lange, R. A. (2016). Treatment of cocaine cardiovascular toxicity: a systematic review. Clinical Toxicology. https://doi.org/10.3109/15563650.2016.1142090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.